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Squamous cell carcinoma antigen belongs to the ser-
pin family and is used for the diagnosis and manage-
ment of squamous cell carcinoma. We investigated
the involvement of squamous cell carcinoma antigen
in psoriasis, as it is always detected in the sera of
patients with psoriasis. Squamous cell carcinoma
antigen localization in psoriatic epidermis varied
depending on its concentration in the patient's sera.
When its level was low in serum, weak and scattered
staining was observed in the granular layer. With a
high concentration of squamous cell carcinoma anti-
gen, strong staining through the suprabasal to granu-
lar layer and condensed staining around the plasma
membrane or intracellular space was detected in the
affected epidermis. Interestingly, squamous cell
carcinoma antigen was abundant in nuclei of the
granular layer cells and elongated rete ridges.
Immunoelectron microscopy con®rmed the localiz-
ation of squamous cell carcinoma antigen in the
nuclei as well as in the periphery of the cell mem-
brane. A cDNA library was constructed from psoria-
tic epidermis and both clones, SCCA1 and SCCA2,
were obtained. Attempts to raise speci®c antibodies
or to prepare cRNA probes for SCCA1 and SCCA2
were unsuccessful because of their nearly identical
structures. A primer pair from each reactive site
sequence enabled us to give a distinctive product for
SCCA1 and SCCA2 by reverse transcription poly-
merase chain reaction. Analysis using these primers
demonstrated that the SCCA2 transcript was specif-
ically expressed in psoriatic skin tissues. Our results
suggest that overexpression of squamous cell carci-
noma antigens is associated with the disease activity
of psoriasis. Key words: cross-class inhibitor/mRNA
expression/protease inhibitor/RT-PCR. J Invest Dermatol
118:147±154, 2002
P
soriasis is a common skin disease characterized by
epidermal hyperproliferation, capillary dilation, and the
presence of acute and chronic in¯ammatory cells in both
the dermis and epidermis (Braun-Falco and Schmoeckel,
1977; Braverman and Sibley, 1982; Baker et al, 1984;
Weinstein et al, 1985; Toruniowa and Jablonska, 1988; Bearskins
et al, 1989). A variety of proteinases as well as their inhibitors that
are not detected in normal skin have been shown in psoriasis (FraÈki
and Hopsu-Havu, 1976; Ohtani et al, 1982; Hopsu-Havu et al,
1983; Sumi et al, 1983; JaÈrvinen et al, 1984; Hibino, 1985; Hibino
et al, 1986, 1988a; Harvima et al, 1990; Kawada et al, 1997).
Overexpression or activation of these proteinases and speci®c
inhibitors are possibly responsible, at least in part, for the disease
activity in psoriasis. Normal epidermis contains three detectable
proteinase inhibitors: plasminogen activator inhibitor 2 (Hibino et
al, 1988b), a trypsin inhibitor (Hibino et al, 1981), and a low
molecular mass cysteine proteinase inhibitor (cystatin) (JaÈrvinen,
1978; Takeda et al, 1986).
We initiated investigation of the changes associated with
inhibitory activities against proteinases in psoriatic skin tissues.
We found increased inhibitory activity on cysteine proteinases, and
puri®ed a protein that strongly inhibited papain and cathepsin L
without affecting cathepsins B or H (Takahashi et al, 1993). A
partial amino acid sequence of this protein revealed similarities to
squamous cell carcinoma antigen (SCCA). The gene for SCCA
localized to human chromosome 18q21.3 with a tandem duplica-
tion of SCCA1 and SCCA2, which encode proteins SCCA1 and
SCCA2, respectively (Suminami et al, 1991; Barnes and Worrall,
1995; Schneider et al, 1995). These encode proteins that are
members of the serine proteinase inhibitor family (serpin), whereas
they inhibit papain-like cysteine proteinases (cathepsins K, L, or S)
and chymotrypsin-like serine proteinases (cathepsin G and mast cell
chymase), respectively. The levels of SCCAs are known to increase
signi®cantly in the sera of psoriatic patients (Duk et al, 1989;
Hamanaka et al, 1997), indicating their use as possible serologic
markers for the diagnosis and management of psoriasis. There is
little information concerning the relationship of serum concentra-
tion and expression in psoriatic skin tissue, however. Furthermore,
which SCCAs are expressed in the psoriatic skin tissues remains
totally unknown.
In this study, we examined the precise distribution and
localization of SCCA in psoriatic skin tissues during different
clinical stages by light and electron microscopic immunohisto-
chemistry. In addition, SCCA mRNA expression in psoriatic skin
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tissues was analyzed by in situ hybridization and reverse transcrip-
tion polymerase chain reaction (RT-PCR). Even though SCCA1
and SCCA2 are nearly identical in primary structure, we designed
speci®c primers to distinguish each molecule by RT-PCR. We
found, for the ®rst time, that SCCA2 was expressed in psoriatic
epidermis.
MATERIALS AND METHODS
Skin specimens Eighteen cases of psoriasis with typical clinical and
histologic features were selected retrospectively. Histopathologic
diagnoses were con®rmed with sections stained by hematoxylin and
eosin. All patients were between 38 and 67 y of age, were in an acute
stage of the disease, and had not yet received treatment. The average
SCCA concentration in sera from patients was 13.2 ng per ml (1.2±
38.2 ng per ml), measured with an IMx-SCC test kit (DaiNabot, Tokyo,
Japan). For RT-PCR, normal skin tissues excised from eight plastic
surgery patients and uninvolved skin distal from nine psoriatic patients
were obtained with informed consent. The tissues were immediately
frozen with liquid nitrogen and stored at ±80°C until use.
Cloning of SCCA1 and SCCA2 cDNA Psoriatic tissue specimens
obtained by shave biopsy were immediately frozen in liquid nitrogen.
Poly(A)+ RNA was isolated from the frozen tissues using FastRNTrack
mRNA isolation (Invitrogen, San Diego, CA). A psoriatic cDNA library
was constructed using TrZAP Express cDNA Synthesis Kit (Stratagene,
La Jolla, CA). Approximately 4 mg of poly(A)-rich RNA from psoriatic
skin was reverse transcribed to cDNA using StrataScript RNaseH±
reverse transcriptase primed with a hybrid oligo(dT) linker primer that
contains the XhoI site. During the second DNA synthesis, EcoRI
adaptors were ligated to the blunt ends. After the XhoI digestion, cDNA
was size fractionated with a Sephacry S-400 spin column. The fraction
with a molecular mass of around 2 kbp was recovered from the column,
inserted into the ZAP expression vector, and packed with GigapackII
Gold (Stratagene). The cDNA was cloned by mixed oligonucleotide
primed ampli®cation cloning (Lee et al, 1988). Two degenerate
oligonucleotides, 5¢-ATACACATCTTTTCATTTTG-3¢ (primer C1)
and 5¢-GCCTGAGAGGTCTGCATCCC-3¢ (primer C2), were
synthesized based on the peptide sequences QYTSFHFAS and
IFNGDADLSG, respectively, whose sequences were obtained by analysis
of the tryptic peptides of the puri®ed protein (C1 and C2 in Fig 1).
When these nucleotides were used as PCR primers, the initial cDNA
ampli®cation from psoriatic skin revealed the presence of a 304 bp
ampli®ed product. The PCR product was sequenced and identi®ed as a
partial nucleotide sequence SCCA cDNA (Suminami et al, 1991). This
speci®c oligonucleotide was used to screen the psoriasis cDNA library.
Twenty-®ve positive clones were obtained by a tertiary screening with
32P-labeled oligonucleotide; however, none contained the 5¢ end. We
employed the 5¢ RACE system (Gibco-BRL, Rockville, MD) to obtain
the 5¢ end. Two gene-speci®c primers, 5¢-AACAGGTCACAAACAG-
AAT-3¢ (primer GSP1) and 5¢-GCAATCAGGTTTACCAGAA-3¢
(primer GSP2), were synthesized based on the sequence of positive
clones from the library, which contained the entire 3¢-untranslated
region (GSP1 and GSP2 in Fig 1). Approximately 1.2 kbp products
were obtained, cloned into the pcDNAII vector (Invitrogen), and
sequenced. The complete sequence of each clone was con®rmed on
both strands. DNA sequences were analyzed with GCG package and
BLAST search programs.
Antigens and antibodies Five antigens were prepared for the
antibody production. SCCA was puri®ed from psoriatic scales as
previously described (Takahashi et al, 1993). Histidine-tagged fusion
SCCA1 and SCCA2 were puri®ed from the homogenates of Escherichia
coli transformed by expression vectors pQE-SCCA1 and pQE-SCCA2,
respectively. Two peptides, AVVGFGSSPTSTNEE and AVVVVELSS-
PSTNEE, corresponding to the respective amino acid residues 348±362
of SCCA1 and SCCA2, were synthesized. A cysteine residue was added
to the NH2-terminus of each peptide, and subsequently conjugated with
keyhole limpet hemocyanin using 3-maleimidebenzoyl-N-hydroxy-
succinimide ester (Kitagawa et al, 1982). Antisera against ®ve antigens
were raised in rabbits, and immunoreactivity was tested against all the
antigens.
In situ hybridization PCR products ampli®ed with common primers
5¢-ATGAATTCACTCAGTGAAGCC-3¢ (primer P1) and 5¢-GGA-
GTGACAGACTAATTGCAT-3¢ (primer P2) (P1 and P2 in Fig 1)
were ligated into pGEM-T vector (Promega, Madison, WI) in order to
construct pGEMT-SCCA1 and pGEMT-SCCA2 vectors. Sense and
antisense RNA probes were prepared according to the manufacturer's
manual (DIG RNA Labeling Kit SP6/T7; Boehringer Mannheim,
Penzberg, Germany). Brie¯y, after linearization of pGEMT-SCCA1 and
pGEMT-SCCA2 with NotI, the antisense or sense cRNA was
transcribed in vitro using digoxigenin-labeled UTP T7 or SP6 RNA
polymerase, respectively. Formalin-®xed and paraf®n-embedded
specimens were sectioned to 5 mm thickness, attached to glass slides
coated with poly-L-lysine, and rapidly air-dried. Dewaxed paraf®n
sections were pretreated with 1 mg per ml of proteinase K for 15 min at
37°C, and ®xed again with 4% paraformaldehyde. Following acetylation
with acetic anhydride in 20 mM Tris-HCl (pH 7.5) and 1 mM
ethylenediamine tetraacetic acid for 10 min, the sections were washed
twice with phosphate-buffered saline (PBS) containing 0.1 M glycine for
15 min. The sections were hybridized with the SCCA1 or SCCA2
riboprobes (1 mg per ml each) in hybridization buffer (50% formamide/
1 3 Denhardt's solution/5 3 sodium citrate/chloride buffer) for 16 h,
and digested with 0.2 mg per ml RNase (DNase-free) in 0.5 M NaCl
and 10 mM Tris-HCl (pH 8.0) for 30 min at 37°C. Sections were then
incubated with 1% blocking reagent (Roche Diagnostics) and
antidigoxigenin antibodies conjugated with alkaline phosphatase.
Hybridized probe was visualized by incubation with enzyme substrate
BM purple (Roche Diagnostics).
RT-PCR analysis of SCCA mRNA expression P1 was used as the
forward primer for SCCA1 and 5¢-CTGATGCATATGAGCTGA-
AGATCG-3¢ (primer P5) for SCCA2. The reverse primers were 5¢-
GTGTAGGACTCCAGATAGCAC-3¢ (primer P10) and 5¢-GTGTAG-
GACTTTAGATACTGA-3¢ (primer P11) for SCCA1 and SCCA2,
respectively (GenBank Accession numbers U19559 for SCCA1 and
U19569 for SCCA2) (P10 and P11 in Fig 1). Total RNA from skin
tissue biopsies was isolated with Isogen (Nippon Gene, Tokyo, Japan)
and genomic DNA was digested with RNase-free DNase I (Promega).
The cDNA was synthesized using the murine moloney leukemia virus
reverse transcriptase (Stratagene) and oligo(dT)17 primer. The PCR
mixture was composed of standard template DNA (pGEMT-SCCA1or
pGEMT-SCCA2) or template cDNA reverse transcribed from 500 ng of
total RNA, 0.2 mM dNTPs, 1.25 pmol primers, and 1 unit AmpliTaq
DNA polymerase (Perkin Elmer, CA) in 20 ml of the reaction buffer.
The endogenous marker, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), was also ampli®ed. Primers used were 5¢-TGGCCAAGG-
TCATCCATGAC-3¢ and 5¢-AGGCCATGCCAGTGAGCTTC-3¢.
PCR was performed by denaturation at 94°C for 1 min, annealing at
62°C (for SCCAs) or 58°C (for GAPDH) for 1 min, and extension at
72°C for 2 min with Iwaki Thermal Sequencer TSR-300 (Iwaki Glass,
Figure 1. SCCA gene locus and cDNA
structure. (A) Structure of the SCCA gene. The
exons are indicated by solid boxes with the
respective numbers above them; introns are
indicated by thin lines. The translation start codon
(atg) and translation stop codon (tag) are shown.
The scale is shown at the top of the ®gure. (B)
Structure of SCCA1 and SCCA2 cDNA. The
shadowed boxes show the open reading frame
regions. The open boxes at each 3¢ and 5¢ region
show noncoding regions. The scale marker
indicates 0.2 kb. Arrowheads below the cDNA
show the position and direction of primers used in
PCR.
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Tokyo, Japan). The PCR-ampli®ed products consisted of 990 and
705 bp for SCCA1and SCCA2, respectively. For semiquantitative RT-
PCR, PCR conditions were carefully examined to stop the reaction
during the exponential phase of ampli®cation of each gene. PCR
products were electrophoresed on a 1.5% agarose gel, stained with
ethidium bromide, and photographed using a Polaroid 667 Instant Pack
Film (Polaroid, UK). To quantify the PCR products, gels were
photographed with Polaroid 665 Positive/Negative Film. The intensity
of the DNA bands on the ®lm was analyzed using densitometry
(Densitograph 3.0, ATTO, Tokyo, Japan).
Immunohistochemistry Skin biopsy specimens were ®xed with 4%
paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.0) for 3 h.
After overnight rinse with PBS, they were embedded in paraf®n. Serial
paraf®n sections were mounted on glass slides, deparaf®nized, rehydrated,
and stained with hematoxylin and eosin. For routine immunohisto-
chemical examination, sections were incubated at room temperature for
60 min with 5% normal goat serum. After washing in PBS, the sections
were incubated with 1:1000 diluted rabbit anti-SCCA IgG overnight and
washed three times in PBS, followed by incubation with peroxidase-
conjugated goat anti-rabbit IgG(H + L). Color was developed on 0.04%
diaminobenzidine and hydroxyperoxide in 50 mM Tris-HCl (pH 7.5).
Control sections were incubated with preimmune rabbit serum.
Immunoelectron microscopy Skin specimens were ®xed with 4%
paraformaldehyde and 0.4% glutalaldehyde in 0.1 M sodium cacodylate
buffer (pH 7.2) for 1 h. The ®xed tissues were washed three times in the
above buffer, embedded in Lowicryl White (London Resin, UK), and
thinly sectioned. The sections were mounted on 150 mesh nickel grids
and incubated with anti-SCCA IgG at a dilution of 1:2000. Secondary
incubation was performed with 15 min gold-particle-labeled goat
antirabbit IgG (ZTMED Laboratory, CA). After immunostaining, the
grids were post®xed with 1% glutaraldehyde solution followed by 1%
uranyl acetate, and observed with a Hitachi H-7100 electron microscope
at 75 kV. Control sections were incubated with preimmune rabbit
serum.
RESULTS
Serum SCCA level correlates well with the intensity of
protein expression in psoriatic epidermis The protein
expression of SCCA in psoriatic skin tissues from patients with
different concentrations in sera was studied immunohisto-
chemically. No positive staining for SCCA was detected in
normal skin tissues (Fig 2A). SCCA staining patterns in psoriatic
epidermis varied considerably with the stage of the lesion based on
psoriasis area and severity index. In early psoriatic lesions showing
the parakeratosis and moderate acanthosis of a low serum level of
SCCA (under 10 ng per ml, 15 cases), relatively weak and scattered
staining was observed in the uppermost portion of the spinous layer
and the granular layer of the epidermis (Fig 2B). Interestingly,
some nuclei in this area were SCCA positive (Fig 2C). Only a few
cells were positive for SCCA in the dermis of psoriatic skin
(Fig 2B). The skin tissues from patients with high SCCA
concentrations in serum (over 10 ng per ml, three cases), which
presented active psoriatic lesions, showed a strong and diffuse
staining from the spinous to granular layers (Fig 2D±I), especially
in active lesions with micropustules of Kogoj (Fig 2F). Most of the
nuclei in the lesion were SCCA positive except in®ltrated
neutrophils. In severe cases, as shown in Fig 2(G), SCCA
staining was detected from the suprabasal layer to the granular
layer. SCCA-positive cells were also seen in the elongated rete
ridges except basal cells (Fig 2H). Condensed staining around the
plasma membrane or intracellular space was frequently observed for
these cells (Fig 2I). The intensity of SCCA staining in psoriatic
epidermis seemed to be correlated well with the SCCA
concentrations in sera, indicating that the presence of SCCA in
the sera of patients with severe psoriatic skin may be due to
leakiness into the circulation.
Immunoelectron microscopy con®rmed localization of
SCCA in nuclei Analysis by immunoelectron microscopy
con®rmed the results of the light microscopy study and further
revealed the precise localization of SCCA in psoriatic epidermis.
The labeling density was relatively low level and randomly
scattered in the corni®ed cell layers, where SCCA-positive opaque
and small round particles were detected in the cytoplasm (Fig 3A).
In the spinous cell layers, strong labeling was found in the cell±cell
contact area (Fig 3B, C). Furthermore, SCCA-positive labeling
was consistently observed in the nucleus (Fig 3D), but the speci®c
nuclear components were not determined. Gold particles were also
demonstrated at the papillary dermis and dermal±epidermal junc-
tion; in particular cytoplasmic granules in mast-cell-like cells and
surrounding degranulated cells were also positive (Fig 3E, F). No
gold particles were detected in control sections.
Analysis of SCCA mRNA expression by in situ hybridiz-
ation We isolated two independent clones from the cDNA
expression library constructed with poly(A)+ RNA from psoriatic
skin. The nucleotide sequences revealed that both clones contained
open reading frames for SCCA1 or SCCA2 cDNA. These clones
can be distinguished by digestion with PstI (Schneider et al, 1995).
Among 25 clones obtained, approximately half the clones (12 clones)
contained a PstI site. We examined the localization of SCCA1 and
SCCA2 mRNA in psoriatic skin tissues by means of in situ
hybridization. Positive signals were localized in the suprabasal
spinous layer and in the lower part of the elongated rete ridges of
psoriatic epidermis, but not in the basal and corneal layers (Fig 4A,
B). No signals were detected in normal skin tissues. The same results
were obtained using antisense SCCA1 cRNA or SCCA2 cRNA,
indicating that neither probe could distinguish between SCCA1 and
SCCA2 mRNA expression. We also tried northern blot analysis and
found an identical hybridization pattern for the total RNAs from
psoriatic skin tissues against both constructs (data not shown). We
concluded that because of the nearly identical primary structures it
would not be possible to separate each by immunohistochemistry, in
situ hybridization, or northern blot analysis.
Establishment of a distinctive method for SCCA1 and
SCCA2 We tried to establish a conventional method for
discrimination of SCCA1 and SCCA2. Speci®c reverse primers
P10 and P11 based on SCCA1 and SCCA2 cDNA were designed
for the PCR analysis (Fig 1). These sequences were chosen
because of the difference in four successive nucleotides at each
reactive site region. Figure 5 shows PCR products of
SCCA1 (990 bp) and SCCA2 (705 bp) independently ampli®ed
with the primer pairs P1/P10 and P5/P11 using SCCA1 and
SCCA2 cDNA templates, respectively. Sequences of these products
were con®rmed as parts of SCCA1 and SCCA2 cDNA,
respectively.
Figure 2. Immunohistochemical staining of SCCA in psoriatic skin tissues. (A) Normal skin. Serum SCCA concentration is < 5 ng per ml.
SCCA staining was negative. (B)±(I) Psoriatic skin. The expression of SCCA in psoriasis was classi®ed into two patterns: (i) diffuse staining in the
cytoplasm and nuclei of epidermal cells (early psoriatic lesion, B) and (ii) condensed staining in the nuclei and plasma membrane/intercellular space
(active psoriatic lesion, D±I). (B) Early psoriatic lesion (serum SCCA concentration 9.4 ng per ml). Upper spinous and granular cells are weakly
positive. Arrowheads indicate SCCA-positive cells in the dermis. (C) High magni®cation of (B). Many nuclei are also positive for SCCA. (D)±(F) Active
psoriatic skin (serum SCCA concentration 21.8 ng per ml). (D) Boundary lesion. Note that SCCA protein is found only in the psoriatic lesion. (E)
High magni®cation of the center part, characterized by elongated rete ridges. (F) Micropustules of Kogoj. Strong SCCA staining is obvious in this area.
Note that parakeratotic cells were SCCA negative. (G)±(I) Very active psoriatic skin (serum SCCA concentration 38.2 ng per ml). Most of the cells
except basal cells are positive for SCCA. (H) High magni®cation of (G), elongated rete ridges. Most of the suprabasal cells are stained. (I) Higher
magni®cation of (G), upper layer. SCCA-positive nuclei and condensed membrane staining are frequently seen. Scale bars: (A) 100 mm; (D) 200 mm;
(B, E, G) 50 mm; (F, H) 20 mm; (I) 10 mm.
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Figure 3. Electron micrographs of psoriatic
skin sections treated with the antibody
against SCCA. (A) Corni®ed cell layer. (B)
Upper part of the spinous cell layer. (C) Higher
magni®cation of (B). Gold particles were mainly
localized along the periphery of the cell±cell
contact area. (D) Higher magni®cation of (B).
SCCA-positive particles are clearly shown in the
nucleus designated N. (E) Filtrated-cell-rich
region near the dermo-epidermal junction marked
with dashes (ep, epidermis; de, dermis). Many
immunoreactive particles were observed in the
cytoplasmic granules of the ®ltrated cells
(arrowheads) and in the surrounding degranulated
cells (arrows). (F) Higher magni®cation of (E).
Many immunoreactive gold particles were
observed in the cytoplasmic granules of ®ltrated
cells. Numbers on the scale bars indicate mm.
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Comparison for tissue levels of mRNA expression between
SCCA1 and SCCA2 We found a reliable method of
distinguishing SCCA1 and SCCA2. Using this method, we tried
to analyze tissue levels of mRNA expression in normal and psoriatic
skin. mRNA concentrations were determined as follows. cDNA
fragments diluted to various concentrations were resolved by
electrophoresis on 1.5% agarose gel and photographed on Polaroid
665 Negative Film. The density measurement demonstrated a
linear correlation for the amount of DNA loaded on the gel in the
range between 10 and 200 ng. The results of RT-PCR analysis
using total RNA obtained from skin tissues of normal and psoriatic
patients are shown in Fig 6. SCCA1 and SCCA2 mRNA
expression can be easily distinguished using these speci®c primer
pairs. Semiquantitative assessment of ampli®ed RT-PCR products
of SCCA mRNA expression revealed that SCCA1 mRNA was
ubiquitously expressed in all normal skin, and signi®cantly
overexpressed in psoriatic skin tissues (Fig 7). On the other
hand, the expression of SCCA2 mRNA was speci®c to psoriatic
skin tissues. None of the normal skin samples showed any positive
band by RT-PCR. Although psoriatic epidermis showed different
staining patterns depending on the serum SCCA levels, the ratio
between SCCA1 and SCCA2 mRNA expression did not show
signi®cant changes.
DISCUSSION
SCCA contains two homologs, SCCA1 and SCCA2, which belong
to the high molecular mass serine proteinase inhibitor superfamily,
serpin (Suminami et al, 1991; Barnes and Worrall, 1995; Schneider
et al, 1995). Although they are nearly identical (92% identical in
nucleotide level), characteristic features of these molecules are
unique inhibition spectra against proteolytic enzymes. SCCA1 is
very different from other serpins and inhibits papain-like cysteine
proteinases, cathepsins K, L, and S (Takeda et al, 1995; Schick et al,
1998). SCCA2 shows ordinary serpin-like properties and inhibits
chymotrypsin-like serine proteinases, cathepsin G and mast cell
chymase (Schick et al, 1997).
Cathepsin L is one of the lysosomal acid proteinases recently
identi®ed in psoriatic epidermis (Kawada et al, 1997). The active
mature form of cathepsin L was con®rmed by immunohisto-
chemistry and Western blot analysis. Also, an increased number of
mast cells was always noticed in the affected skin and various
proteinases including tryptase, chymase, and cathepsin G are
supposed to be released by degranulation (Harvima et al, 1990;
Schechter et al, 1990). Indeed, chymase activity was detected in the
papillary dermis of the psoriatic lesion (Harvima et al, 1993). Our
immunoelectron microscopy study demonstrated that SCCAs were
predominantly present along the periphery of the intercellular space
in the upper spinous cell layer of psoriatic epidermis from patients
with a high serum SCCA level. In addition, SCCA immuno-
reactivity was detected around the degranulated cells near the
Figure 5. Distinctive ampli®cation for SCCA1 and SCCA2.
Speci®city of cDNA ampli®cation was tested for SCCA1 (lanes 1 and 2)
and SCCA2 (lanes 3 and 4) by PCR. PCR was performed using P1/P10
(lanes 1 and 3) and P5/P11 (lanes 2 and 4) primer pairs, respectively.
Each template concentration (pGEMT-SCCA1 or pGEMT-SCCA2) was
2 ng. The right lane shows molecular weight markers (fX174RT DNA/
HaeIII fragments).
Figure 6. RT-PCR analysis of SCCA mRNA expression.
Expression of SCCA1 and SCCA2 mRNA in psoriatic skin as well as
normal tissues was analyzed by RT-PCR. Lanes 1, 2, normal skin tissues;
lanes 3±6, psoriatic skin tissues from four patients.
Figure 4. In situ hybridization of SCCA mRNAs in psoriatic
epidermis. (A) In situ hybridization using the antisense SCCA1 cRNA
probe. Positive signals were localized in the suprabasal spinous layer, but
not in the supracorneal and basal layers. (B) In situ hybridization with a
sense SCCA1 cRNA probe. No positive signal was observed. Scale bars:
100 mm.
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dermo-epidermal junction as well as in the granules of ®ltrated
cells. Collectively, these ®ndings strongly suggest that SCCAs play a
protective role against various proteinases in pathophysiologic
events of psoriasis.
Strong positive staining for SCCAs was also found in nuclei of
granular layer cells and a considerable number of cells in the
elongated rete ridges, although we could not ®nd any known
nuclear localization signal in these molecules. The presence of
SCCAs in nuclei was con®rmed by immunoelectron microscopy.
Nuclei for SCCA-positive cells were intact and did not show any
morphologic changes. Although we tried to obtain speci®c
antibodies against SCCA1 or SCCA2, none of the preparations
contained monospeci®c antibody. Antibodies including peptide
antibodies directed against the respective reactive site sequences also
reacted with both SCCAs. Western blot analysis of the extracts
from psoriatic skin tissues demonstrated a band of approximately Mr
45 kDa, which corresponds to the SCCA proteins (data not
shown). It is unlikely that other proteins cross-reacting with
antibodies against SCC in nuclei are present. At this point, we do
not know which SCCA is localized in the nuclei of psoriatic
epidermis. It is highly probable that SCCAs work as proteinase
inhibitors in psoriatic skin. Localization of SCCA in nuclei seems to
suggest a novel pathologic function in psoriatic keratinocytes,
however. Interestingly, primary structures of SCCAs indicate that
they are involved in the subfamily ``ovserpin'' (Schneider et al,
1995). Ovserpin includes ovalbumin, plasminogen activator
inhibitor 2, maspin, and CrmA (Potempa et al, 1994). Of these,
CrmA is known as the inhibitor of apoptosis (Miura et al, 1993).
Although CrmA belongs to the ovserpin, it inhibits speci®c
cysteine proteinases, caspases, executors of apoptosis (Ray et al,
1992; Komiyama et al, 1994). Recently, overexpression of SCCA1
in cancer cells contributed to their survival by mediating protection
from apoptosis (Suminami et al, 2000). It would be interesting to
see whether SCCAs play a role in apoptotic processes in skin.
In this study, SCCA mRNA was detected only in the spinous
layer of psoriatic epidermis but not in normal epidermis by in situ
hybridization. On the other hand, it has been reported that SCCA
mRNA is localized in the basal and suprabasal layers of normal
squamous epithelium in human gynecologic tissues (Takeshima et
al, 1992). This discrepancy might be explained by the differences in
environmental conditions in psoriatic epidermis. Numa et al (1996)
showed that tumor necrosis factor a stimulated the production of
SCCA in normal human epidermal keratinocytes. Tumor necrosis
factor a has been considered to be one of the modulators related to
the promotion of in¯ammatory cells in psoriatic skin (Kristensen
et al, 1993). Overexpression of SCCA mRNAs would probably be
due, at least in part, to the production of cytokines in psoriatic
tissues.
By use of speci®c primer sets, we have succeeded in selectively
amplifying SCCA1 and SCCA2. The SCCA1 transcript was
ubiquitously expressed in all skin tissues tested, although we have
not detected any immunoreactive SCCA in sera and skin tissues
from normal individuals. This is probably due to the low expression
level of SCCA1 in normal tissues, as an enhanced immunohisto-
chemical method using True Blueâ showed weak but considerable
staining in the granular layer of normal epidermis (unpublished
data). We observed considerable upregulation of SCCA1 mRNA
in psoriatic skin compared to normal skin. In contrast, none of the
normal skin tissues showed any expression of SCCA2 mRNA.
SCCA2 mRNA was exclusively expressed in psoriatic skin. These
pieces of evidence suggest that in psoriatic epidermis SCCA1 is
overexpressed and SCCA2 is newly transcribed and is absent in
normal epidermis.
In this study, we showed expression and localization of SCCAs
in psoriatic skin by means of in situ hybridization, immuno-
histochemistry, and immunoelectron microscopy. In addition, RT-
PCR analyses using speci®c primers revealed, for the ®rst time, the
presence of SCCA2 in psoriatic skin.
The authors thank Ms. T. Yamamoto, Mr. T. Suzuki, and Ms. M. Nakano for
their technical assistance.
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